The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3

Journal of Clinical Pathology

Volumn 64, Issue 4, 2011, Pages 303-307

  Øvestad, Irene Tveiterås ^a,c   Gudlaugsson, Einar ^a,c   Skaland, Ivar ^a   Malpica, Anais ^b   Munk, Ane Cecilie ^a,c   Janssen, Emiel A M ^a   Baak, Jan P ^a,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; HISTONE H3; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY KI 67; PROTEIN CK 13; PROTEIN CK 14; PROTEIN P16; PROTEIN P53; PROTEIN P63; RETINOBLASTOMA PROTEIN; SYNDECAN 1; TRANSCRIPTION FACTOR FOXP3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CLASSIFICATION; CANCER REGRESSION; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENDOMETRIUM; FEMALE; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCHEMISTRY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS GENE;

BIOPSY; CD8-POSITIVE T-LYMPHOCYTES; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENOTYPE; HUMANS; NEOPLASM REGRESSION, SPONTANEOUS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 79953094970     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.083626     Document Type: Article

References (24)

1. Horner MJRL, Krapcho M, Neyman N, et al. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute, 2009. http://seer.cancer. gov/csr/1975-2006/based on November 2008 SEER data submission, posted to the SEER web site.
2. Ostor A. The natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-92. (Pubitemid 23095196)
3. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425-34.
4. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 2009;9:119.
5. Albrechtsen S, Rasmussen S, Thoresen S, et al. Pregnancy outcome in women before and after cervical conisation: population based cohort study. BMJ 2008;337:a1343.
6. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.
7. McCluggage WG, Bharucha H, Caughley LM, et al. Interobserver variation in the reporting of cervical colposcopic biopsy specimens: comparison of grading systems. J Clin Pathol 1996;49:833-5. (Pubitemid 26338564)
8. Kruse AJ, Baak JP, Helliesen T, et al. Evaluation of MIB-1-positive cell clusters as a diagnostic marker for cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26:1501-7. (Pubitemid 35239427)
9. Baak JP, Kruse AJ, Robboy SJ, et al. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol 2006;59:1017-28. (Pubitemid 44570323)
10. Ovestad IT, Gudlaugsson E, Skaland I, et al. Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Mod Pathol 2010;23:1231-40.
11. Schaeffer AJ, Nguyen M, Liem A, et al. E6 and E7 oncoproteins induce distinct patterns of chromosomal aneuploidy in skin tumors from transgenic mice. Cancer Res 2004;64:538-46.
12. Zielinski GD, Snijders PJ, Rozendaal L, et al. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003;201:535-43. (Pubitemid 38256402)
13. Kruse AJ, Baak JP, Janssen EA, et al. Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model. Cell Oncol 2004;26:13-20. (Pubitemid 39108239)
14. Tsoumpou I, Arbyn M, Kyrgiou M, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35:210-20.
15. Kruse AJ, Skaland I, Munk AC, et al. Low p53 and retinoblastoma protein expression in cervical intraepithelial neoplasia grade 3 lesions is associated with coexistent adenocarcinoma in situ. Hum Pathol 2008;39:573-8.
16. Soreide K. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J Clin Pathol 2009;62:1-5.
17. Zuna RE, Allen RA, Moore WE, et al. Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type. Mod Pathol 2007;20:167-74. (Pubitemid 46422170)
18. Zuna RE, Allen RA, Moore WE, et al. Comparison of human papillomavirus genotypes in high-grade squamous intraepithelial lesions and invasive cervical carcinoma: evidence for differences in biologic potential of precursor lesions. Mod Pathol 2004;17:1314-22. (Pubitemid 39472985)
19. Insinga RP, Dasbach EJ, Elbasha EH, et al. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16:709-15.
20. He W, Staples D, Smith C, et al. Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J Virol 2003;77:10566-74. (Pubitemid 37129700)
21. Funk JO, Waga S, Harry JB, et al. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997;11:2090-100. (Pubitemid 27369103)
22. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36. (Pubitemid 120035062)
23. Thomas MC, Chiang CM. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 2005;17:251-64. (Pubitemid 40138619)
24. Cid-Arregui A. Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol J 2009;3:67-83.